--- title: "Puma BioTech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 44.81 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285621479.md" datetime: "2026-05-07T21:14:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285621479.md) - [en](https://longbridge.com/en/news/285621479.md) - [zh-HK](https://longbridge.com/zh-HK/news/285621479.md) --- # Puma BioTech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 44.81 M Revenue: As of FY2026 Q1, the actual value is USD 44.81 M, beating the estimate of USD 42 M. EPS: As of FY2026 Q1, the actual value is USD -0.07, beating the estimate of USD -0.17. EBIT: As of FY2026 Q1, the actual value is USD -4.099 M. Puma Biotechnology, Inc. operates in a single reporting segment focused on the development and commercialization of innovative products to enhance cancer care . #### Segment Revenue - **Total Revenue**: Decreased from $46.0 million in Q1 2025 to $44.8 million in Q1 2026, representing a $1.2 million decrease . - **Product Revenue, Net**: Decreased to $42.0 million in Q1 2026 from $43.1 million in Q1 2025, primarily due to higher deductions for variable consideration, partially offset by an increased selling price . - **Royalty Revenue**: Remained consistent at $2.9 million for both Q1 2026 and Q1 2025 . #### Operational Metrics - **Net (Loss) Income**: Puma Biotechnology, Inc. reported a net loss of -$3.8 million in Q1 2026, a decline from a net income of $3.0 million in Q1 2025 . - **Cost of Sales**: Was $10.4 million in Q1 2026, consistent with $10.6 million in Q1 2025 . - **Selling, General and Administrative (SG&A) Expenses**: Increased by $0.8 million (4.7%) to $18.4 million in Q1 2026 from $17.6 million in Q1 2025 . Payroll and related costs increased by $0.9 million (10.6%) to $9.1 million in Q1 2026 . Professional fees and expenses increased by $0.4 million (9.4%) to $5.0 million in Q1 2026 . Provision for credit loss decreased by -$0.2 million (-100.0%) to $0 million in Q1 2026 . - **Research and Development (R&D) Expenses**: Increased by $5.9 million (42.8%) to $19.8 million in Q1 2026 from $13.9 million in Q1 2025 . Clinical trial expense increased by $5.2 million (143.1%) to $8.8 million in Q1 2026, driven by increased alisertib study activity . Internal R&D expense increased by $0.7 million (8.4%) to $9.3 million in Q1 2026, primarily due to increased employee compensation . - **Interest Expense**: Decreased to -$0.7 million in Q1 2026 from -$2.2 million in Q1 2025 . - **Other Income**: Decreased to $0.1 million in Q1 2026 from $0.4 million in Q1 2025 . #### Cash Flow - **Net Cash Provided by Operating Activities**: Increased to $15.4 million in Q1 2026 from $3.6 million in Q1 2025 . This increase was primarily due to a $27.3 million decrease in accounts receivable and a $3.1 million increase in accounts payable, partially offset by an -$11.7 million decrease in accrued expenses and other, and a $3.2 million increase in inventory . - **Net Cash Provided by Investing Activities**: Increased to $2.5 million in Q1 2026 from $1.5 million in Q1 2025, mainly due to the maturity of $27.3 million in available-for-sale securities, partially offset by $24.9 million in new purchases . - **Net Cash Used in Financing Activities**: Remained consistent at -$11.3 million for both Q1 2026 and Q1 2025, including $11.1 million for principal payments and $0.2 million for exit fees on debt . - **Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash**: Resulted in an increase of $6.6 million in Q1 2026, compared to a decrease of -$6.2 million in Q1 2025 . #### Unique Metrics - **Cash and Cash Equivalents**: $36.2 million as of March 31, 2026, an increase from $29.6 million as of December 31, 2025 . - **Marketable Securities**: $65.4 million as of March 31, 2026, a decrease from $67.9 million as of December 31, 2025 . - **Working Capital**: $82.5 million as of March 31, 2026, an increase from $81.4 million as of December 31, 2025 . - **Current Portion of Long-Term Debt**: $11.3 million as of March 31, 2026, a decrease from $22.5 million as of December 31, 2025 . - **Stockholders’ Equity**: $128.4 million as of March 31, 2026, a decrease from $130.3 million as of December 31, 2025 . - **Intangible Assets, Net**: $39.0 million as of March 31, 2026, with an estimated remaining useful life of 4.0 years and future amortization expense of approximately $7.3 million for the remainder of 2026, $9.7 million for each year from 2027 through 2029, and $2.4 million for 2030 . - **Total Potential Milestone Payments (Sub-license Agreements)**: Approximately $579.8 million as of March 31, 2026 . - **Unrecognized Employee Compensation Cost**: Approximately $1.7 million for non-vested stock options and $8.8 million for non-vested RSUs as of March 31, 2026 . - **401(k) Employer-Matching Contributions**: $0.6 million in Q1 2026, compared to $0.5 million in Q1 2025 . #### Future Outlook and Strategy Puma Biotechnology, Inc. anticipates significant expenses for the development of alisertib in 2026 . The company expects its existing cash, cash equivalents, and marketable securities, combined with projected product sales and sub-license payments, to meet operating cash needs for at least one year after the report’s filing . However, future funding could be affected by market conditions, the commercialization success of NERLYNX, alisertib development, regulatory decisions, or clinical trial results . ### Related Stocks - [PBYI.US](https://longbridge.com/en/quote/PBYI.US.md) ## Related News & Research - [Puma Biotech CFO Maximo F. Nougues disposes of 9,386 shares for $77,560.24](https://longbridge.com/en/news/292125961.md) - [What to Expect From Adobe’s Q3 2026 Earnings Report](https://longbridge.com/en/news/293933244.md) - [JSL updates financial events calendar for 2026](https://longbridge.com/en/news/294067473.md) - [The Cooper Companies’ Q2 2026 Earnings: What to Expect](https://longbridge.com/en/news/293747625.md) - [Stanley Black & Decker announces R$ 0.72 per unit distribution for Q3 2026](https://longbridge.com/en/news/293793888.md)